This Plain Language Summary of publication article (PLSP) from Future Oncology discusses two clinical trials, SPOTLIGHT and GLOW, focused on treating CLDN18.2-positive and HER2-negative stomach or gastroesophageal junction (GEJ) cancers. Both trials examined whether adding zolbetuximab to chemotherapy could improve outcomes for people with locally advanced, or metastatic cancer. The trials found that combining zolbetuximab with chemotherapy helped patients live longer before their tumors grew or new tumors appeared, and also increased overall survival compared to chemotherapy alone.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial’ and was published in The Lancet.

Visit The Lancet using the link to read the original article.